rss
Br J Ophthalmol 2003;87:521-522 doi:10.1136/bjo.87.5.521
  • Editorial

What more is there to learn about trachoma?

  1. M Melese1,
  2. W Alemayehu1,
  3. B Gaynor2,
  4. E Yi2,
  5. J P Whitcher2,
  6. T M Lietman2
  1. 1ORBIS International, Ethiopia
  2. 2FI Proctor Foundation and the Department of Ophthalmology, University of California, San Francisco, USA
  1. Correspondence to: John P Whitcher, MD, Department of Ophthalmology, FI Proctor Foundation, University of California, San Francisco, 95 Kirkham Street, Room 308, San Francisco, CA 94143–0944, USA; nepal{at}itsa.ucsf.edu

    There is hope that trachoma will be the first major bacterial disease eliminated by a worldwide effort

    A few minutes spent searching Medline reveals some interesting trends: while the total number of scientific publications has exploded over the past 35 years, the number of papers incorporating the keyword “trachoma” has actually decreased (Fig 1A). The number of reviews of trachoma, however, has increased (Fig 1B). Is this a sign that the study of trachoma has matured—that effective treatments are well known and that the only challenge left is to implement them? Many recent editorials have indeed suggested that a wide variety of treatments are effective.1–6 In fact, studies suggest that trachoma is disappearing even in the absence of a programme specifically targeting the disease.7–10 Is the war against trachoma, or at least the scientific part, finally over?

    The past decade has witnessed numerous advances in chlamydia research: the chlamydial genome has been sequenced,11 diagnosis with sensitive nucleic acid amplification tests has become routine,12–14 and randomised clinical trials have purported to demonstrate the efficacy of behavioural,15 pharmacological,16 and even entymological17 control measures in reducing the prevalence of trachoma. A course of three doses of oral azithromycin administered to all members of a community was shown to be as effective as a 6 week course of topical tetracycline.18 This is important because compliance with oral azithromycin is clearly far superior. Another trial suggested that an …

    Responses to this article

    This Article

    Services

    1. Request permissions

    Social bookmarking

    Register for free content


    Free sample
    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
    View free sample issue >>

    Free archive
    The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
    Register to access the free archive >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.